Payment overview · 2025
General Payments
$206.08
14 reported records · 2 companies
Healthcare provider profile · identity verified
Peter A Andrews, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · STRUTHERS, OH · NPI 1275541468
Verified facts
What the public records show
CMS Open Payments records show Peter A Andrews, D.O. received $206.08 in general payments during 2025 across 14 reported records.
PFIZER INC. accounted for 71.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.76 | 71.2% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.32 | 28.8% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.08 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $146.76 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $146.76 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.32 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.32 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 451 | 86 |
| Losartan Potassium | Losartan Potassium | 445 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 404 | 86 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 318 | 31 |
| Lisinopril | Lisinopril | 306 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 301 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 267 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 247 | 46 |
| Gabapentin | Gabapentin | 244 | 47 |
| Metformin Hcl | Metformin Hcl | 242 | 55 |
| Omeprazole | Omeprazole | 223 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 36 |
| Furosemide | Furosemide | 179 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 33 |
| Potassium Chloride | Potassium Chloride | 156 | 32 |
| Alprazolam | Alprazolam | 150 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 27 |
| Meloxicam | Meloxicam | 146 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 13 |
| Trazodone Hcl | Trazodone Hcl | 104 | 17 |
| Simvastatin | Simvastatin | 103 | 25 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 99 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 19 |
| Pregabalin | Pregabalin | 89 | 11 |
| Eliquis | Apixaban | 84 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 13 |
| Sertraline Hcl | Sertraline Hcl | 78 | 15 |
| Lorazepam | Lorazepam | 77 | 18 |
| Jardiance | Empagliflozin | 76 | 14 |
| Cefdinir | Cefdinir | 73 | 66 |
| Famotidine | Famotidine | 73 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 16 |
| Spironolactone | Spironolactone | 67 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 11 |
| Allopurinol | Allopurinol | 64 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 64 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 54 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 53 | suppressed |
| Azithromycin | Azithromycin | 52 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 37 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 11 |
| Meclizine Hcl | Meclizine Hcl | 50 | 16 |
| Ozempic | Semaglutide | 50 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 50 | suppressed |
| Glipizide | Glipizide | 49 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 11 |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Prednisone | Prednisone | 47 | 16 |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Ezetimibe | Ezetimibe | 43 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Folic Acid | Folic Acid | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Enulose | Lactulose | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.08 · 14 records | PFIZER INC. | ELIQUIS, NURTEC ODT, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error